Pre-order Enquiry
Request Free Sample
Chemotherapy Induced Neutropenia (CIN)- Market Insight, Epidemiology and Market Forecast - 2028
SKU ID : DEL-13736207 | Publishing Date : 01-Jan-2019 | No. of pages : 100
Request Sample
Request Customization
Check DiscountsDetailed TOC of Chemotherapy Induced Neutropenia (CIN)- Market Insight, Epidemiology and Market Forecast - 2028
1. Report Introduction2. Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance
2.1. Market Share Distribution of Chemotherapy Induced Neutropenia (CIN) in 2016
2.2. Market Share Distribution of Chemotherapy Induced Neutropenia (CIN) in 2028
3. Disease Background and Overview: Chemotherapy Induced Neutropenia (CIN)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Chemotherapy Induced Neutropenia (CIN) in 7MM
4.3. Total Prevalent Patient Population of Chemotherapy Induced Neutropenia (CIN) in 7MM – By Countries
5. Epidemiology of Chemotherapy Induced Neutropenia (CIN) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN)
5.1.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) *
5.1.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)*
5.1.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN)
5.1.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN)
5.4.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)*
5.4.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)*
5.4.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN)
5.4.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN)
5.5.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)*
5.5.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)*
5.5.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN)
5.5.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN)
5.6.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)*
5.6.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)*
5.6.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN)
5.6.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN)
5.7.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)*
5.7.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)*
5.7.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN)
5.7.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN)
5.8.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)*
5.8.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)*
5.8.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN)
5.8.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN)
5.9.3. Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN)*
5.9.4. Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN)*
5.9.5. Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN)
5.9.6. Treatable Cases of the Chemotherapy Induced Neutropenia (CIN)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Chemotherapy Induced Neutropenia (CIN)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Chemotherapy Induced Neutropenia (CIN)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Chemotherapy Induced Neutropenia (CIN): 7MM Market Analysis
12.1. 7MM Market Size of Chemotherapy Induced Neutropenia (CIN)
12.2. 7MM Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN)
12.3. 7MM Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products
13. Chemotherapy Induced Neutropenia (CIN): Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in United States
13.1.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in United States
13.1.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in Germany
13.2.1.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in Germany
13.2.1.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in France
13.2.2.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in France
13.2.2.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in Italy
13.2.3.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in Italy
13.2.3.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in Spain
13.2.4.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in Spain
13.2.4.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in United Kingdom
13.2.5.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Chemotherapy Induced Neutropenia (CIN) in Japan
13.3.2. Percentage Share of drugs marketed for Chemotherapy Induced Neutropenia (CIN) in Japan
13.3.3. Market Sales of Chemotherapy Induced Neutropenia (CIN) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
*Indication Specific
List of Figures, Tables and Charts Available in Chemotherapy Induced Neutropenia (CIN)- Market Insight, Epidemiology and Market Forecast - 2028
Table 1: Total Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in 7MMTable 2: Total Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Table 6: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Table 7: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Table 12: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Table 15: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Table 16: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Table 17: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Table 22: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Table 27: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Table 31: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Table 32: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Table 37: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Table 42:7MM- Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Table 45: United States-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Table 48: Germany-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Table 51: France-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Table 54: Italy-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Table 57: Spain-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Table 60:UK-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Table 63: Japan-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 1: Total Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Figure 7: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Figure 12: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Figure 16: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Figure 17: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Figure 22: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Figure 27: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Figure 32: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Figure 37: Treatable Cases of the Chemotherapy Induced Neutropenia (CIN) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Figure 42:7MM- Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Figure 45: United States-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Figure 48: Germany-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Figure 51: France-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Figure 54: Italy-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Figure 57: Spain-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Figure 60:UK-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Chemotherapy Induced Neutropenia (CIN) in USD MM (2016-2028)
Figure 63: Japan-Market Share Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD MM (2016-2028)
